Factors affecting survival time after recurrence of non-small-cell lung cancer treated with concurrent chemoradiotherapy

Yasushi Hamamoto, Naoyuki Nogami, Shuichi Shinohara, Masaaki Kataoka, Toshiyuki Kozuki, Tetsu Shinkai, Yuka Kato

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose Dose-fractionation schedules of palliative or salvage radiotherapy (RT) for recurrence of non-small-cell lung cancer (NSCLC) are various because they highly depend on patient prognosis. For optimal selection of dosefractionation schedules, factors affecting survival time after recurrence were examined. Materials and methods From 1992 to 2005, 115 patients with stage III NSCLC received curative-intent concurrent chemoradiotherapy (CCRT). Among these patients, 74 underwent recurrence and were reviewed. Evaluated factors were age at recurrence, gender, initial stage, histological subtype, initial radiation-field size, recurrent patterns (locoregional alone vs. distant ± locoregional), time to recurrence (≤6 vs. >6 months), and treatment for recurrence (chemotherapy, RT). Results Median follow-up time after recurrence was 7 (range 0-59) months. One- and 2-year overall survival rates after recurrence were 28 and 11%, respectively. Based on multivariate analysis, time to recurrence (p = 0.0001) and administration of chemotherapy for recurrence (p = 0.0190) were the independently significant factors. Conclusions Early recurrence was the most significant factor for survival after post-CCRT recurrence of NSCLC. Administration of chemotherapy for recurrence was also a significant factor, whereas RT for recurrence was not significant. When RT was given to patients with post-CCRT recurrence of NSCLC, dose-fractionated schedules should be determined considering these factors.

Original languageEnglish
Pages (from-to)249-254
Number of pages6
JournalJapanese Journal of Radiology
Volume30
Issue number3
DOIs
Publication statusPublished - Apr 2012
Externally publishedYes

Fingerprint

Chemoradiotherapy
Non-Small Cell Lung Carcinoma
Recurrence
Survival
Radiotherapy
Appointments and Schedules
Drug Therapy
Dose Fractionation
Age Factors

Keywords

  • Chemoradiotherapy
  • Non-small-cell lung cancer
  • Palliative radiotherapy
  • Prognostic factor
  • Recurrence

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Factors affecting survival time after recurrence of non-small-cell lung cancer treated with concurrent chemoradiotherapy. / Hamamoto, Yasushi; Nogami, Naoyuki; Shinohara, Shuichi; Kataoka, Masaaki; Kozuki, Toshiyuki; Shinkai, Tetsu; Kato, Yuka.

In: Japanese Journal of Radiology, Vol. 30, No. 3, 04.2012, p. 249-254.

Research output: Contribution to journalArticle

Hamamoto, Yasushi ; Nogami, Naoyuki ; Shinohara, Shuichi ; Kataoka, Masaaki ; Kozuki, Toshiyuki ; Shinkai, Tetsu ; Kato, Yuka. / Factors affecting survival time after recurrence of non-small-cell lung cancer treated with concurrent chemoradiotherapy. In: Japanese Journal of Radiology. 2012 ; Vol. 30, No. 3. pp. 249-254.
@article{5ca7526cd96845278e59c0f9a23d13ad,
title = "Factors affecting survival time after recurrence of non-small-cell lung cancer treated with concurrent chemoradiotherapy",
abstract = "Purpose Dose-fractionation schedules of palliative or salvage radiotherapy (RT) for recurrence of non-small-cell lung cancer (NSCLC) are various because they highly depend on patient prognosis. For optimal selection of dosefractionation schedules, factors affecting survival time after recurrence were examined. Materials and methods From 1992 to 2005, 115 patients with stage III NSCLC received curative-intent concurrent chemoradiotherapy (CCRT). Among these patients, 74 underwent recurrence and were reviewed. Evaluated factors were age at recurrence, gender, initial stage, histological subtype, initial radiation-field size, recurrent patterns (locoregional alone vs. distant ± locoregional), time to recurrence (≤6 vs. >6 months), and treatment for recurrence (chemotherapy, RT). Results Median follow-up time after recurrence was 7 (range 0-59) months. One- and 2-year overall survival rates after recurrence were 28 and 11{\%}, respectively. Based on multivariate analysis, time to recurrence (p = 0.0001) and administration of chemotherapy for recurrence (p = 0.0190) were the independently significant factors. Conclusions Early recurrence was the most significant factor for survival after post-CCRT recurrence of NSCLC. Administration of chemotherapy for recurrence was also a significant factor, whereas RT for recurrence was not significant. When RT was given to patients with post-CCRT recurrence of NSCLC, dose-fractionated schedules should be determined considering these factors.",
keywords = "Chemoradiotherapy, Non-small-cell lung cancer, Palliative radiotherapy, Prognostic factor, Recurrence",
author = "Yasushi Hamamoto and Naoyuki Nogami and Shuichi Shinohara and Masaaki Kataoka and Toshiyuki Kozuki and Tetsu Shinkai and Yuka Kato",
year = "2012",
month = "4",
doi = "10.1007/s11604-011-0040-9",
language = "English",
volume = "30",
pages = "249--254",
journal = "Japanese Journal of Radiology",
issn = "1867-1071",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Factors affecting survival time after recurrence of non-small-cell lung cancer treated with concurrent chemoradiotherapy

AU - Hamamoto, Yasushi

AU - Nogami, Naoyuki

AU - Shinohara, Shuichi

AU - Kataoka, Masaaki

AU - Kozuki, Toshiyuki

AU - Shinkai, Tetsu

AU - Kato, Yuka

PY - 2012/4

Y1 - 2012/4

N2 - Purpose Dose-fractionation schedules of palliative or salvage radiotherapy (RT) for recurrence of non-small-cell lung cancer (NSCLC) are various because they highly depend on patient prognosis. For optimal selection of dosefractionation schedules, factors affecting survival time after recurrence were examined. Materials and methods From 1992 to 2005, 115 patients with stage III NSCLC received curative-intent concurrent chemoradiotherapy (CCRT). Among these patients, 74 underwent recurrence and were reviewed. Evaluated factors were age at recurrence, gender, initial stage, histological subtype, initial radiation-field size, recurrent patterns (locoregional alone vs. distant ± locoregional), time to recurrence (≤6 vs. >6 months), and treatment for recurrence (chemotherapy, RT). Results Median follow-up time after recurrence was 7 (range 0-59) months. One- and 2-year overall survival rates after recurrence were 28 and 11%, respectively. Based on multivariate analysis, time to recurrence (p = 0.0001) and administration of chemotherapy for recurrence (p = 0.0190) were the independently significant factors. Conclusions Early recurrence was the most significant factor for survival after post-CCRT recurrence of NSCLC. Administration of chemotherapy for recurrence was also a significant factor, whereas RT for recurrence was not significant. When RT was given to patients with post-CCRT recurrence of NSCLC, dose-fractionated schedules should be determined considering these factors.

AB - Purpose Dose-fractionation schedules of palliative or salvage radiotherapy (RT) for recurrence of non-small-cell lung cancer (NSCLC) are various because they highly depend on patient prognosis. For optimal selection of dosefractionation schedules, factors affecting survival time after recurrence were examined. Materials and methods From 1992 to 2005, 115 patients with stage III NSCLC received curative-intent concurrent chemoradiotherapy (CCRT). Among these patients, 74 underwent recurrence and were reviewed. Evaluated factors were age at recurrence, gender, initial stage, histological subtype, initial radiation-field size, recurrent patterns (locoregional alone vs. distant ± locoregional), time to recurrence (≤6 vs. >6 months), and treatment for recurrence (chemotherapy, RT). Results Median follow-up time after recurrence was 7 (range 0-59) months. One- and 2-year overall survival rates after recurrence were 28 and 11%, respectively. Based on multivariate analysis, time to recurrence (p = 0.0001) and administration of chemotherapy for recurrence (p = 0.0190) were the independently significant factors. Conclusions Early recurrence was the most significant factor for survival after post-CCRT recurrence of NSCLC. Administration of chemotherapy for recurrence was also a significant factor, whereas RT for recurrence was not significant. When RT was given to patients with post-CCRT recurrence of NSCLC, dose-fractionated schedules should be determined considering these factors.

KW - Chemoradiotherapy

KW - Non-small-cell lung cancer

KW - Palliative radiotherapy

KW - Prognostic factor

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=84863187860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863187860&partnerID=8YFLogxK

U2 - 10.1007/s11604-011-0040-9

DO - 10.1007/s11604-011-0040-9

M3 - Article

C2 - 22311092

AN - SCOPUS:84863187860

VL - 30

SP - 249

EP - 254

JO - Japanese Journal of Radiology

JF - Japanese Journal of Radiology

SN - 1867-1071

IS - 3

ER -